| Description | Maxacalcitol (22-Oxacalcitriol) is a ligand of VDR-like receptors and a non-serum calcium vitamin D3 analogue. Maxacalcitol inhibits parathyroid hormone (PTH) mRNA expression in vitro and in vivo. |
| In vitro | Maxacalcitol 在体外和体内抑制甲状旁腺激素(PTH)的mRNA表达，并且与全反式维甲酸联合使用时，能够抑制骨肉瘤的肿瘤生长。Maxacalcitol 在类骨细胞中展现出与calcitriol相似的效果。 |
| Synonyms | 马沙骨化醇, 22-Oxacalcitriol |
| molecular weight | 418.61 |
| Molecular formula | C26H42O4 |
| CAS | 103909-75-7 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 100 mg/mL (238.89 mM), Sonication is recommended. |
| References | 1. Karashima T, et al. Successful Treatment of Bowen's Disease with Topical Maxacalcitol.Acta Derm Venereol. 2012 Jan 26. 2. Monier-Faugere, et al. 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int. (1999)55 821. 3. Inoue K, et al. Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3.Lab Invest. 2012 Aug 27. 4. Barroga, et al. Inhibitory effects of 22-oxa-calcitriol and all-trans retinoic acid on the growth of a canine osteosarcoma derived cell-line in vivo and its pulmonary metastasis in vivo. Res.Vet.Sci. (2000)68 79. |